KLOW
80 mg
€ 120,00
per vialAvailableKLOW — 80 mg per research vial: GHK-Cu 50 mg, TB-500 10 mg, BPC-157 10 mg and KPV 10 mg. For research purposes only. Not for human consumption or therapeutic use.
Vial sets
1 vial · € 120,00 total · + € 4,99 PostNL shipping per order
- Reference
- MVP / 004
- Strength
- 80 mg
- Availability
- Available
- Handling
- Store cool and dry, away from light. Laboratory handling only.
- Shipping
- PostNL within the Netherlands, € 4,99 per order
Specification
For research only. Not for human use.
Key research areas
- Multi-peptide interaction research (GHK-Cu, TB-500, BPC-157, KPV)
- Connective-tissue and fibroblast biology
- Inflammatory-signalling modulation
- Cell migration and tissue-outgrowth models
- Comparative blend-versus-component analysis
Potential benefits observed in research
- Combines four compounds individually linked to tissue-repair research.
- Pairs collagen-pathway support (GHK-Cu) with inflammatory-pathway modulation (KPV).
- Offers researchers a single model for studying peptide synergy.
- Component studies report cell-migration and survival effects in connective-tissue models.
Reported observations from published studies under controlled conditions. They do not establish the safety, quality or performance of this research material.
Research documentation
KLOW — 80 mg
KLOW combines GHK-Cu 50 mg, TB-500 10 mg, BPC-157 10 mg and KPV 10 mg, providing a stated total of 80 mg per vial. The formulation brings together components investigated across connective-tissue biology and inflammatory signalling. GHK-Cu has been studied in fibroblast and collagen models, while BPC-157 research has examined tendon-cell migration and survival. KPV has been investigated for peptide transport and inflammatory pathways in cell and animal models. TB-500 belongs to an area of peptide-fragment research where sequence verification is essential.
Key Research Areas
- Connective-tissue biology
- fibroblast activity
- inflammatory signalling
- peptide transport
- mixture interactions
Researchers could investigate how these distinct components interact, but complementary research interests do not demonstrate an effective combination. The cited ingredient studies do not establish clinical efficacy, safety or synergy for this exact blend. GHK-Cu research; BPC-157 research; KPV research; TB-500 review.
For research purposes only. Not for human consumption or therapeutic use.
